Articles related to REAL-WORLD EVIDENCE

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

A retrospective cohort study of 349,168 propensity-matched patients with diabetes found a hazard ratio of 2.22 for nonarteritic anterior ischemic optic neuropathy among semaglutide users compared with non-GLP-1 RA antidiabetic therapy users, with elevated risk emerging at two years and persisting through four years of follow-up.

Opioid prescribing for cancer patients reporting no pain declined substantially across a single Connecticut health system from 2016 to 2020, while prescribing for patients reporting pain remained stable.

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Prenatal exposure to medications that inhibit sterol biosynthesis was associated with higher rates of autism spectrum disorder diagnosis in a 6.14-million-record retrospective analysis.